Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MMP1 | P03956 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | GNG2 | P59768 | 1/20 | 0.53 |
| ▸ | GNB1 | P62873 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558063 | 0.90 | NPC1 (0.52) | MMP9KMT2AMMP1NPC1RAB9A | |
| SCHEMBL5354568 | 0.87 | MMP9 (0.68) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3239662 | 0.84 | MMP9 (0.54) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3237123 | 0.84 | MMP9 (0.54) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3237103 | 0.83 | MMP9 (0.64) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3245122 | 0.81 | MMP9 (0.58) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3244101 | 0.80 | MMP9 (0.57) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3236207 | 0.79 | OPRL1 (0.60) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3236262 | 0.79 | MMP9 (0.63) | MMP9KMT2AMMP1MEN1ALOX15 | |
| SCHEMBL3231124 | 0.79 | PRKCI (0.59) | MMP9KMT2AMMP1MEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235558-B2 | Inhibitors of the GPIb—vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | claimed |
| EP-1509516-B1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-31 | — | — | EP | claimed |
| EP-1509516-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | Aventis Pharma Deutschland GmbH (DE) | 2005-03-02 | — | — | EP | claimed |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-08 | — | — | US | claimed |
| WO-2003104221-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | claimed |
| EP-1369420-A1 | Inhibitors of the GPib - vWF interaction | Aventis Pharma Deutschland GmbH (DE) | 2003-12-10 | — | — | EP | claimed |
| US-7745443-B2 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070173489-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-26 | — | — | US | disclosed |
| US-7235558-B2 | Inhibitors of the GPIb—vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| EP-1509516-B1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-31 | — | — | EP | disclosed |
| EP-1509516-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | Aventis Pharma Deutschland GmbH (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| WO-2003104221-A1 | INHIBITORS OF THE GPIB -VWF INTERACTION, THEIR PREPARATION AND USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-18 | — | — | WO | disclosed |
| EP-1369420-A1 | Inhibitors of the GPib - vWF interaction | Aventis Pharma Deutschland GmbH (DE) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173489-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | F13B, F11, F12 | MMP9 872/4885KMT2A 4648/4885MMP1 3903/4885 |
| US-20040067980-A1 | Inhibitors of the GPIb-vWF interaction, their preparation and use | F13B, F11, F12 | MMP9 946/4885KMT2A 4662/4885MMP1 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.